Somai Pharmeceuticals

In a landmark decision, the U.S. Drug Enforcement Administration (DEA) is reportedly moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, sparking varied reactions across the industry. MariMed’s (OTC:MRMD) Enthusiastic Endorsement Bob Fireman, CEO of MariMed,...